• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OptiNose Inc. (Amendment)

    2/14/24 8:48:50 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPTN alert in real time by email
    SC 13G/A 1 rosalind_mdwd_13ga_14Feb2024.htm Schedule 13G

    SC 13G Mediwound_13G.htm SC 13G


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A
    (Amendment No. 1)

    Under the Securities Exchange Act of 1934

    MEDIWOUND LTD.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    M68830104

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G

     

    Page 2 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Advisors, Inc.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER  
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    479,990 shares of Common Stock

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.2%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

     

     

     

     


    1 This percentage is calculated based upon 9,219,261 ordinary shares of the Issuer’s common stock outstanding as of September 30, 2023 as reported by the Issuer. However, as more fully described in Item 3, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


    CUSIP No. M68830104

     

    13G

     

    Page 3 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    479,990 shares of Common Stock

    163,265 Shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.2%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


    CUSIP No. M68830104

     

    13G

     

    Page 4 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gilad Aharon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    479,990 shares of Common Stock

    163,265 Shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.2%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


     

     

     

     

     

    CUSIP No. M68830104

     

    13G

     

    Page 5 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    479,990 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)  ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.2%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

     

     

     

     

     

     

     

     

     

     


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G

     

    Page 6 of 9 Pages

     

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer: MEDIWOUND LTD.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices
    42 Hayarkon Street, Yavne, Israel 8122745.

     

     

     

    Item 2.

     

    (a)

    Name of Person Filing

    Rosalind Advisors, Inc. (“Advisor” to RMF)

    Rosalind Master Fund L.P. (“RMF”)

    Steven Salamon (“President”)

    Steven Salamon is the portfolio manager of the Advisor which advises RMF.

    Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

     

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence
    Rosalind Advisors, Inc.

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Rosalind Master Fund L.P.

    P.O. Box 309

    Ugland House, Grand Cayman

    KY1-1104, Cayman Islands

     

    Steven Salamon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Gilad Aharon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

     

     

     

    (c)

    The principal business of Rosalind Advisors, Inc. is to operate as an investment advisory firm and to make public equity investments. The principal occupation of Mr. Salamon is serving as the Portfolio Manager and President of Rosalind Advisors, Inc., which advises Rosalind Master Fund L.P.

     

     

     

     

    (d)

    No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

     

     

     

    (e)

    No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     

     

     

    (f)

    Mr. Salamon and Mr. Aharon are citizens of Canada, resident in Ontario


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


     

     

     

     

     

    CUSIP No. M68830104

     

    13G

     

    Page 7 of 9 Pages

     

     

     

     

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

    ¨

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

     

    (b)

    ¨

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (c)

    ¨

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    ¨

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    ¨

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ¨

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ¨

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ¨

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    ¨

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

     

     

     

     

    (a)

     

    Amount beneficially owned:  

     

    The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 13 of the cover page for each Reporting Person is based upon 9,219,261 Ordinary shares of the Issuer’s common stock outstanding as of September 30, 2023 as reported by the Issuer.

    Rosalind Master Fund L.P. is the record owner of 479,990 shares of common stock and 163,265 shares of Common Stock issuable upon exercise of warrants.  

    Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.  Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.  

     

     

     

     

     

     

    (b)

     

    Percent of class:  

    Rosalind Advisors, Inc. –  5.2%

    Rosalind Master Fund L.P. –  5.2%

    Steven Salamon –  5.2%

    Gilad Aharon –  5.2%

     

     

     

     

     


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


     

     

     

     

     

    CUSIP No. M68830104

     

    13G

     

    Page 8 of 9 Pages

     

     

     

     

     

     

    (c)

     

    Number of shares as to which the person has:  

     

     

     

    (i)

    Shared power to vote or to direct the vote  

    Rosalind Advisors, Inc. –  479,990

    Rosalind Master Fund L.P. –  479,990

    Steven Salamon – 479,990

    Gilad Aharon - 479,990

     

     

     

     

     

     

     

     

    (ii)

    Sole power to dispose or to direct the disposition of  – 0

     

     

     

     

     

     

     

     

    (iii)

    Shared power to dispose or to direct the disposition of  

    Rosalind Advisors, Inc. –  479,990

    Rosalind Master Fund L.P. –  479,990

    Steven Salamon –  479,990

    Gilad Aharon - 479,990

     

     

     

     

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

    Instruction. Dissolution of a group requires a response to this item.

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Item 7 – 9.  Not Applicable


     

    NYC#: 139632.2


    SC 13G Mediwound_13G.htm SC 13G


     

     

     

     

     

    CUSIP No. M68830104

     

    13G

     

    Page 9 of 9 Pages

     

     

     

     

     

    Item 10.  Certification.

     

     

     

     

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    2/14/2024

    Date

     

     

    Signature

     

    Steven Salamon/President Rosalind Advisors, Inc.

    Name/Title

     

     

    Exhibit A

    Joint Filing Agreement

     

    The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Mediwound Ltd. is filed jointly, on behalf of each of them.

     

     

    Rosalind Advisors, Inc.

    By: _____________________________

    Name: Steven Salamon

    Title: President

     

    Rosalind Master Fund L.P.

    By: _____________________________

    Name: Mike McDonald

    Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

     

    By: _____________________________

    Name: Steven Salamon


     

    NYC#: 139632.2

    Get the next $OPTN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPTN

    DatePrice TargetRatingAnalyst
    3/20/2025Buy → Hold
    Lake Street
    1/3/2025$5.00 → $18.00Buy
    H.C. Wainwright
    3/11/2024$5.00Buy
    H.C. Wainwright
    8/21/2023$3.00Buy
    Lake Street
    10/21/2022$5.00Buy
    Jefferies
    More analyst ratings

    $OPTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer & Corp Sec Marino Michael F Iii returned 125,204 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - OptiNose, Inc. (0001494650) (Issuer)

      5/21/25 9:26:54 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kohler Terry returned 30,541 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - OptiNose, Inc. (0001494650) (Issuer)

      5/21/25 9:26:25 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fletcher R John

      4 - OptiNose, Inc. (0001494650) (Issuer)

      5/21/25 9:26:21 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Financials

    Live finance-specific insights

    See more
    • Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

      BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

      5/21/25 8:26:34 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

      YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

      3/19/25 9:45:38 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

      Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025 BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under w

      3/19/25 9:25:02 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

      BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

      5/21/25 8:26:34 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

      Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2024, and provided recent operational highlights. Fourth Quarter 2024 and Recent Highlights New Prescriptions (NRx) and Total Prescriptions (TRx)An inflection in prescription demand first

      3/26/25 7:00:00 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

      YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

      3/19/25 9:45:38 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    SEC Filings

    See more
    • SEC Form EFFECT filed by OptiNose Inc.

      EFFECT - OptiNose, Inc. (0001494650) (Filer)

      5/22/25 12:15:04 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by OptiNose Inc.

      EFFECT - OptiNose, Inc. (0001494650) (Filer)

      5/22/25 12:15:09 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by OptiNose Inc.

      EFFECT - OptiNose, Inc. (0001494650) (Filer)

      5/22/25 12:15:06 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by OptiNose Inc.

      SC 13G - OptiNose, Inc. (0001494650) (Subject)

      11/20/24 5:21:26 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

      SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

      11/14/24 4:54:20 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

      SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

      11/12/24 10:32:10 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Leadership Updates

    Live Leadership Updates

    See more
    • Optinose Appoints Terry Kohler as Chief Financial Officer

      YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide

      10/7/24 4:59:53 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Announces CEO Transition and Business Update

      YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s

      1/31/23 7:00:00 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Optinose Appoints Paul Spence as Chief Commercial Officer

      YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,

      12/15/22 4:30:00 PM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • OptiNose downgraded by Lake Street

      Lake Street downgraded OptiNose from Buy to Hold

      3/20/25 8:56:55 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on OptiNose with a new price target

      H.C. Wainwright reiterated coverage of OptiNose with a rating of Buy and set a new price target of $18.00 from $5.00 previously

      1/3/25 7:58:58 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on OptiNose with a new price target

      H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00

      3/11/24 7:44:36 AM ET
      $OPTN
      Biotechnology: Pharmaceutical Preparations
      Health Care